Document is current

Article History

Received: 2 August 2019

Accepted: 13 January 2020

First Online: 31 January 2020

Ethics approval and consent to participate

: The IMPACt study protocol was approved by a central institutional review board (Aspire IRB). The following institutions used local institutional review boards: Akron General Medical Center, Alliance Cancer Specialists, Columbia St. Mary’s Hospital, Aurora Cancer Care, Budway Surgical Associates, Community Hospital Northwest Oncology, Northwestern Medicine, Roswell Park Cancer Institute, Herbert-Herman Cancer Center, St. Joseph’s Hospital, Stephenson Cancer Center, and TriHealth Cancer Institute. The study was registered with clinicaltrials.gov (NCT02670577). Prior to enrollment, patients provided written informed consent to participate and for research use of their tumor samples and for collection of clinical data.

: Not applicable.

: SU, HMK, TT, and WA are employees of Agendia, Inc. HS reports receiving personal fees outside the submitted work from Novartis, Eli Lilly, AstraZeneca, Celgene, PUMA, Pfizer, and Eisai. RM reports receiving personal fees outside the submitted work from Agendia, Pfizer, Novartis, Eli Lilly, Amgen, PUMA, and Eisai. BM reports receiving honoraria outside the submitted work from Celgene and Janssen. No other disclosures were reported.